IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018
November 26 2018 - 3:35PM
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that it will present data on its
DPX-RSV program at “RespiDART: Frontiers in Drug Development
against Respiratory Viruses.” The conference will take place in
Miami, Florida, from November 29 - 30, 2018 at the Marriott Miami
Biscayne Bay.
Members of IMV’s leadership will share data via an oral
presentation as well as a poster session. Details are as
follows:
Name:
|
‘Evaluation of the therapeutic potential of antibody and T cell
targeted immune responses towards RSV Small Hydrophobic
protein’ |
Presenter: |
Genevieve
Weir, PhD, Director of Research, IMV Inc. |
|
Oral Presentation:
|
Oral
Abstracts, Session 3 |
Date: |
Friday,
November 30, 2018 |
Time: |
12:00 –
12:10 p.m. ET |
Location: |
Grand
Ballroom |
|
Poster Presentation:
|
Abstract
#105 |
Date/Time: |
November
29 at 3:00 p.m. to November 30 at 6:00 p.m. ET |
Location: |
Salon F
& G |
|
|
About RESPIDART
RespiDART is a new addition to the DART series of healthcare
conferences and is focused on drug development challenges and
advances for respiratory virus threats to human health. These
viruses include long-standing threats such as RSV and influenza, as
well as recent outbreaks of MERS-coV, parainfluenza virus, and
metapneumovirus. This meeting will focus on advances in
therapeutics, vaccinology, virus/host interactions and enzymology,
and new study models in development. By bringing together world
leaders and key opinion holders, RespiDART 2018 aims to address the
latest challenges in vaccine and drug development against
respiratory viruses.
About IMV
IMV Inc., formerly Immunovaccine Inc., is a clinical
stage biopharmaceutical company dedicated to making immunotherapy
more effective, more broadly applicable, and more widely available
to people facing cancer and other serious diseases. IMV is
pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology
leverages a novel mechanism of action that enables the programming
of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac as a combination therapy in
multiple clinical studies with Incyte and Merck. Connect
at www.imv-inc.com.
Contacts for IMV:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E:
info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about IMV Inc (Toronto Stock Exchange): 0 recent articles
More News Articles